Phathom Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue more than doubled year-over-year, driven by strong VOQUEZNA adoption among GI specialists and an expanded sales force. Guidance for 2026 is maintained, with operating profitability targeted by Q3 and positive cash flow in 2027.
-
VOQUEZNA’s focused GI strategy is driving strong revenue growth, with 2026 set as a pivotal year for profitability and cash flow. The company’s capital structure is now sustainable, and long-term growth will be supported by expanding into primary care and leveraging first-mover advantage.
-
Leadership implemented a strategic pivot to gastroenterology, cut operating expenses by 50%, and restructured finances to support sustainable growth. The company projects strong revenue growth, targets a $1 billion market in GI, and expects exclusivity until at least 2033.
-
A focused GI specialist strategy has driven strong growth for VOQUEZNA, with revenue rising to $175 million and a clear path to $1–2 billion in annual sales. Regulatory exclusivity extends to 2032, and financial discipline supports profitability by H2 2026.
-
A strategic pivot to focus on gastroenterologists drove strong revenue growth and improved expense discipline, with profitability expected in late 2026. The company targets deep GI market penetration, leverages exclusivity extensions, and plans to launch additional GI assets before VOQUEZNA's loss of exclusivity.
Fiscal Year 2025
-
Delivered strong 2025 results with 217% revenue growth and improved margins, driven by GI strategy and sales force execution. Enhanced capital structure and issued 2026 guidance for $320–$345 million revenue, targeting profitability by Q3 and cash flow positivity in 2027.
-
A strategic pivot to focus on gastroenterology sales has halved operating expenses and driven revenue growth, with Q3 results and script trends suggesting outperformance. Profitability is targeted for 2026, with future growth expected from patient advocacy and potential OTC conversion.
-
VOQUEZNA is focused on patients with persistent gastroesophageal reflux symptoms after PPI failure, with a strategic sales shift to gastroenterology driving strong growth. The company targets $1 billion in annual revenue within two to three years, supported by robust exclusivity and broad commercial coverage.
-
A focused GI sales strategy has driven strong revenue growth and improved financial discipline, with 3% market penetration and significant room for expansion. Physician adoption is staged and driven by patient outcomes, while Medicare access and pipeline developments support future growth.
-
VOQUEZNA is driving strong growth by targeting gastroenterologists, with Q3 revenue up 23% and prescriptions up 28%. Operating expenses have been significantly reduced, and the company is on track for profitability in 2024. Market exclusivity extends to 2032, with further upside from ongoing EoE trials.
-
Q3 2025 saw 25% revenue growth and a 43% reduction in operating expenses, with strong execution on a GI-focused strategy and improved cash usage. Full-year guidance was raised, and the company remains on track for operating profitability in 2026, supported by robust prescription growth and disciplined cost management.
-
VOQUEZNA is experiencing rapid revenue and prescription growth, driven by a strategic focus on gastroenterologists and strong product differentiation over PPIs. Profitability is targeted for 2026, with ongoing pipeline expansion into EOE and confirmed exclusivity protection through at least 2032.
-
VOQUEZNA targets millions of GERD patients unresponsive to PPIs, with a sales strategy now focused on gastroenterologists for higher productivity and adoption. Regulatory exclusivity extends into 2033, supporting a multi-year growth runway and plans for profitability and future pipeline expansion.
-
Q2 2025 saw strong VOQUEZNA growth, with 39% sequential revenue increase and a strategic focus on gastroenterologists. Cost-saving measures reduced OpEx, and 2025 revenue guidance was raised to $165–$175 million, with profitability expected in 2026.
-
Leadership is accelerating commercial focus on GI specialists and refining the target market to patients with persistent pain. FDA exclusivity through 2032 enables long-term planning, while cost reductions and a shift in marketing strategy support a path to profitability by 2026.
-
A new reflux therapy is driving strong early growth, with a strategic shift to focus on gastroenterologists and a 40% reduction in operating expenses. Profitability is targeted for 2026, with further value creation expected from portfolio expansion and a pending FDA exclusivity decision.
-
The meeting covered director elections, auditor ratification, and executive compensation votes, all of which passed. No stockholder questions were raised, and final voting results will be filed in a Form 8-K.
-
VOQUEZNA is rapidly gaining adoption in the GI and primary care markets, driven by strong patient outcomes and a differentiated mechanism. Strategic focus is on deepening GI penetration, maintaining revenue growth, reducing OpEx, and awaiting a key FDA exclusivity decision, with profitability targeted for 2026.
-
Voquezna prescriptions and prescriber base continued to grow in Q1 2025, with net revenues of $28.5 million and strong gross margins. Cost-saving initiatives and leadership changes aim to achieve profitability in 2026 without further financing, while regulatory exclusivity remains a key uncertainty.
-
Management outlined a strategy focused on revenue growth, efficient market access, and profitability, with VOQUEZNA showing strong uptake and expanding prescriber base. Awaiting key FDA exclusivity decision in June, while maintaining robust financial runway and evaluating pipeline and partnership opportunities.
-
Vonoprazan has shown clinical superiority over PPIs and is expanding into new indications like EoE, with phase II trials starting soon. Commercial growth is strong, with over 80% coverage and increasing retail prescriptions, while regulatory exclusivity decisions are expected by June.
Fiscal Year 2024
-
2024 saw rapid VOQUEZNA adoption, with over 300,000 prescriptions and strong revenue growth, driven by FDA approval for non-erosive GERD and expanding commercial coverage. 2025 guidance includes increased DTC investment, a new EoE trial, and a focus on primary care adoption.
-
Prescription growth remains strong, with expanding access and a shift toward primary care prescribers. Regulatory exclusivity is being pursued through a Citizen Petition, while OTC transition is a longer-term strategy. Sales momentum is expected to continue into 2024.
-
VOQUEZNA's launch has disrupted the GERD market with rapid physician and payer adoption, driven by its fast onset and durability. Regulatory exclusivity and IP strategies aim to extend protection, while new clinical programs and a capped royalty financing support future growth.
-
Voquezna's launch is accelerating with strong commercial coverage, robust prescription growth, and expanding prescriber base, especially in primary care. Regulatory exclusivity is expected through 2032, with new programs targeting EoE and on-demand use. Financial outlook remains positive.
-
Q3 2024 saw strong revenue growth, expanded Voquezna access, and a successful $130M equity raise. Over 143,000 prescriptions have been filled, with primary care adoption accelerating and gross margin reaching 86%. Cash position is robust, supporting continued investment and growth.
-
Voquezna is gaining traction as a novel GERD therapy, with rapid uptake, expanding commercial coverage, and strong DTC-driven demand. Fill rates and prescriber engagement are rising, and new clinical programs aim to further expand its use and displace PPIs.
-
Q2 2024 saw Voquezna's FDA approval for non-erosive GERD, broadening its market and driving a 283% sequential revenue increase to $7.3M, with 122,000 prescriptions written and 77% commercial coverage secured. Cash runway is expected through 2026.
-
Prescription volume and fill rates are rising post-launch, with commercial coverage expanding and a major market opportunity expected from the upcoming non-erosive GERD approval. Lifecycle management includes new studies and formulations, while international expansion will focus on partnerships.
-
VOQUEZNA’s Q1 launch exceeded expectations with $1.9 million revenue and strong script demand. Coverage now reaches 48% of commercial lives, with further expansion and a major label extension for non-erosive GERD expected in Q3. Blockbuster potential is supported by clinical superiority and a large market.